TBILISI, GEORGIA--(Marketwired - December 04, 2013) -
Cromos™ Pharma, a premier full-service CRO with operations in Ukraine, Belarus, Georgia, Russia and the countries of Central/Eastern Europe, announced today the appointment of Dr. Tsira Jibladze, MD, MPH as the Country Head for the Republic of Georgia.
"Georgia is a strategic location for Cromos™ Pharma and we are very excited that Dr. Jibladze has decided to join our team," said Dr. Vladimir Bogin, company's CEO. "She is arguably the most respected clinical trials expert in the country and her knowledge and leadership is a tremendous asset in Cromos™ Pharma's ongoing harmonization of its international operations and service offerings."
Dr. Jibladze graduated with an MD degree in Cardiology from the Tbilisi State Medical University where she also received a Master of Public Health degree. Prior to embarking on a very successful career in clinical research, Dr. Jibladze excelled as the head of Tbilisi's branch of the Red Cross and then as the department head at the Ministry of Health of Georgia.
"I look forward to bringing Cromos™ Pharma's operations in Georgia to new heights," said Dr. Jibladze. "With its streamlined and expeditious regulatory approval process, developed health care system and unparalleled recruitment potential Georgia is at the dawn of becoming a premier destination for clinical trials and Cromos™ Pharma has all the right attributes that will allow it to dominate this promising market."
About Cromos™ Pharma, LLC
Cromos™ Pharma, LLC is a regional contract research organization (CRO) with operations in Ukraine, Belarus, Georgia, Russia and Eastern/Central Europe and a business development office in the United States. The company provides a full spectrum of trial-related services which include regulatory approvals, medical writing, feasibility assessments, monitoring, project management and warehousing. Cromos™ Pharma, LLC is a privately owned company. Lloyd's of London is Cromos™ Pharma's underwriter of professional and general liability insurance.